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Edited by Stuart FergusonAbstract P84N5 is a death domain containing protein that
interacts with the tumor suppressor retinoblastoma protein and
induces apoptosis. We cloned and characterized two novel
alternatively spliced versions of p84N5. The p84N5 short isoform
(p84N5s) lacks the death domain and does not induce apoptosis.
We showed that p84N5, but not p84N5s, is cell cycle regulated.
We found that p84N5-GFP chimera can rapidly shuttle between
the nucleus and the cytoplasm. Taken together, these observa-
tions suggest that p84N5 may transmit signals from the nucleus
to cytoplasmic eﬀectors.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Numerous evidences indicate that apoptosis is tightly con-
nected to cell cycle checkpoints; for example, DNA damage in
dividing cells results in cell cycle block and often induction of
apoptosis [1,2]. Although the main eﬀectors of either pathways
are well characterized, in particular the p53-dependent path-
ways [3,4], the details of a direct interaction between the cell
cycle machinery and apoptosis deserve further investigation.
The tumor suppressor retinoblastoma protein (Rb) plays a
major role in cell cycle and apoptosis [5]; in particular, hypo-
phosphorylated Rb inhibits cell proliferation primarily
through its ability to bind and modulate distinct transcription
factors including E2F-1 [6]. A role for Rb in protection from
apoptosis has also been demonstrated; studies on Rb deﬁcient
mice suggest that in addition to E2F, other molecules may
mediate Rb-regulated apoptosis [7].
The protein p84N5 was originally identiﬁed because it in-
teracts with Rb [8]. More recently, it was also shown to be part
of the TREX complex [9]. Further studies demonstrated that
p84N5 possesses a nuclear localization signal (NLS) and a
death domain (DD) in its C-terminal region [10,11]. The DD is
a protein binding domain found in molecules involved in in-
ﬂammation and apoptosis [12,13]. A pro-apoptotic function of* Corresponding author. Fax: +39-0331-581233.
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Abbreviations: DAPI, 4,6-diamidino-2-phenylindole; GFP, green ﬂuo-
rescent protein; RT-PCR, real time polymerase chain reaction
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p84N5-induced apoptosis [11]. These data suggest that p84N5
may play a role in connecting cell cycle regulation to the ap-
optotic machinery. However, the regulation of the expression
of p84N5 and the mechanistic details of its action are ill de-
ﬁned. The aim of this study was to characterize at a molecular
level the protein p84N5.2. Materials and methods
2.1. Antibodies
Murine anti-p84N5 antibody (clone 5E10) was from GeneTex (San
Antonio, TX); murine anti-Myc monoclonal antibody (clone 9B11)
was from Cell Signaling Technology (Beverly, MA); murine anti-
tubulin-a antibody was from Sigma–Aldrich (St. Louis, MO); murine
anti-cyclin D1 polyclonal antibody and murine anti-cyclin B1 mono-
clonal antibody (clone GNS-11) were from BD Pharmingen (San
Diego, CA); anti active-caspase3 antibody was from Promega (Madi-
son, WI); FluorolinkTM Cy3TM labeled anti-mouse and anti-rabbit
antibodies were from Amersham Pharmacia Biotech (Little Chalfont,
UK).
2.2. Plasmids and constructs
Full-length and alternatively spliced coding sequences of p84N5
were ampliﬁed by polymerase chain reaction (PCR) from human lung,
kidney and fetal brain cDNA libraries purchased from Clontech (Palo
Alto, CA) and cloned into pcDNA3.1(+) vector (Invitrogen, Carlsbad,
CA) or pEGFP-C1 and pEGFP-N1 vectors (BD Biosciences Clontech,
Palo Alto, CA). The V5-tagged XIAP expression plasmid was obtained
from ResGen (Invitrogen Corporation, Carlsbad, CA); the AU1-tag-
ged FADD construct has been described previously [14].
2.3. Cell lines and transfection
Normal human dermal ﬁbroblast (NHDF) cells were obtained from
PromoCell (Heidelberg, Germany), HeLa 293, U2OS and SAOS2 cells
were obtained from the American Type Culture Collection (Manassas,
VA, USA).
HeLa and U2OS cells were transfected with the LipofectamineTM
2000 kit (Invitrogen, Carlsbad, CA). 293 cells were transfected with the
CalPhos Mammalian Transfection Kit (BD Biosciences Clontech, Palo
Alto, CA, USA).
2.4. Cell cycle and apoptosis analysis
Analysis of cell cycle distribution was conducted by propidium io-
dide staining and ﬂow cytometry by using FACScan (Beckton Dick-
inson, Franklin Lakes, NJ). Cell cycle subpopulations (G1, S and G2/
M) were quantiﬁed with the software ModFit LT v3.0, purchased from
Verity Software House (Topsham, ME, USA).
Apoptosis induction was conﬁrmed and quantiﬁed by scoring of
apoptotic nuclear morphology after staining with 4,6-diamidino-
2-phenylindole (DAPI). Alternately, cells were stained with anti
active-caspase3 antibody and quantiﬁed by scoring of active-caspase3
positive cells after staining with DAPI.ation of European Biochemical Societies.
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Real time PCR (RT-PCR) was ampliﬁed using the Applied Biosys-
tems ‘‘real time’’ version of the assay on the ABI Prism 7900 thermal-
cycler and Sybr green MasterMix (Applied Biosystems, Foster City,
CA). Full-length p84N5 amplicon was ampliﬁed using the following
primers: 50-AGC AATCACTTTGGATTGAAGATA-30 (forward)
and 50-GGGGGTTTTCAGATA GTAGTTGAT-30 (reverse); the
short isoform p84N5s amplicon was ampliﬁed with the following
primers: 50-AGCAATCACTTTGGATTGAAGA-30 (forward) and 50-
CATGGGTTTGTTGCGTGT-30 (reverse). The analysis of RT-PCR
output data followed the manufacturer-suggested DDCt method, that
provides the target gene expression value as unitless fold changes in the
unknown sample compared to a calibrator sample, represented by a
cDNA mix of 12 human tissues, retro-transcribed from RNA
(Clontech, Palo Alto, CA). mRNA levels were normalized on the
global expression of four housekeeping genes (18S, GUS, CPH and
actin).2.6. Immunoﬂuorescence and time lapse microscopy
Fluorescence photomicrographs were obtained by means of an
Axiovert S100 inverted microscope (Zeiss, G€ottingen, Germany),
equipped with a charge-coupled device (CCD) camera VarioCam
(PCO Computer Optics, Germany).
Time lapse microscopy was performed with the Cell Observer system
(Zeiss, G€ottingen, Germany) based on a inverted ﬂuorescence micro-
scope Axiovert 200M (Zeiss, G€ottingen, Germany), equipped with an
AxioCam CCD camera (Zeiss, G€ottingen, Germany). The software
AxioVision (Zeiss, G€ottingen, Germany) was used to acquire the im-
ages and to process the movies.Fig. 1. (A) Schematic representation of p84N5, p84N5s and p84N5s2; the pR
293 cells were transfected with the indicated constructs, ﬁxed and stained for
U2OS cells were transfected with the indicated constructs together with pEG
apoptotic nuclear morphology (the meansS.D. of 3 replicates are shown; *,3. Results
3.1. Identiﬁcation of alternatively spliced versions of p84N5
Screening of public cDNA databases revealed the existence
of distinct transcripts encoding for diﬀerent isoforms of
p84N5. Two novel p84N5 alternative splicing isoforms were
cloned by PCR from three human cDNA libraries (GenBank
Accession Nos. AY573302 and AF573303, respectively). We
named these two novel short isoforms as p84N5s and p84N5s2
(Fig. 1).
Sequence analysis of p84N5s revealed the presence of an
additional 100 bp sequence within the exon 14 containing an
in-frame stop codon. Evidences support the fact that the se-
quence is introduced by alternative splicing: ﬁrst, sequence
ends follow the canonical ‘‘GT-AG rule’’ usually valid for
splicing consensus motifs [15]. Second, this extra sequence was
previously annotated in the genomic locus of p84N5 (Locus
ID: 9984).
Intriguingly, the coding sequence of p84N5s (1185 nucleo-
tides) lacks the Rb-binding domain, as well as the NLS and the
DD. Therefore, p84N5s is predicted to encode for a natural
p84N5 truncated form, which has a unique C-terminal se-
quence of 15 amino acids (VSSTRNKPMIEKMEI).
The junction sequence between the exon 14 and the extra
exon unique to p84N5s (ATGAGCAATCACTTTGGATT-b binding domain (pRb BD), the NLS and the DD are indicated. (B)
indirect immunoﬂuorescence using anti-Myc antibody and DAPI. (C)
FP. Apoptosis was assessed by scoring of GFP-transfected cells with
P < 0:05 versus pcDNA3 group; **, P < 0:005 versus pcDNA3 group).
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ACACGCA ACAAACCCATGATTGAAAAAATGGAAAT-
TTAG) was used as a query to screen ESTs databases with
BLAST algorithm: several human mouse and rat ESTs mat-
ched the query, conﬁrming that p84N5s is conserved in
mammalians (data not shown).
P84N5s2 contains an additional sequence of 43 nucleotides
between the exons 4 and 5 (Locus ID 9984). An in-frame stop
codon is present in this sequence, resulting in a putative coding
sequence of 258 nucleotides. The predicted product is a trun-
cated p84N5 form, containing the ﬁrst 85 amino acids and a
unique alanine in C-terminus. So far, only one EST has been
identiﬁed in public database for this p84N5 novel short iso-
form (GenBank Accession No.: BG723448).3.2. Characterization of the short isoform p84N5s
Immunostaining analysis showed that p84N5s localizes to
the cytoplasm; on the contrary, p84N5 primarily localizes
within the nucleus (Fig. 1B and [8]).
p84N5 has been characterized as a pro-apoptotic factor:
when over-expressed, it induces apoptosis in vitro [11]. We
checked if p84N5s retains any pro-apoptotic activity. The os-
teosarcoma cell line U2OS was transfected with expression
vectors encoding for the following constructs: pcDNA3.1, the
inhibitor of apoptosis protein XIAP (as a negative control),
p84N5, p84N5s or FADD (as a positive control), in the
presence of pEGFP. After 24 h, apoptosis was quantiﬁed by
manual scoring of green ﬂuorescent protein (GFP)-transfected
cells with nuclear apoptotic morphology (Fig. 1C). Cells
transfected with p84N5 showed low but signiﬁcant apoptosis
induction (more than 25%), whereas apoptosis levels of cells
transfected with XIAP or p84N5s were comparable to negative
controls (pcDNA3.1), below 8%. Interestingly, the apoptotic
index of p84N5-transfected cells was considerably lower, in
comparison with apoptosis induced by FADD transfection
(about 80%). This evidence indicates that although both pro-
teins contain a DD and induce apoptosis, p84N5 mechanism
or kinetic may be diﬀerent with respect to FADD.
In contrast, p84N5s does not induce apoptosis at any con-
centration tested; this may be due to either mislocalization to
the cytoplasm or lack of a functional DD.3.3. P84N5 and p84N5s expression in normal and tumoral
tissues
It has been previously shown that p84N5 is ubiquitously
expressed in normal tissues [8].
The expression levels of p84N5 and p84N5s were quantiﬁed
in a panel of 28 cell lines. Fibroblasts (NHDF, BJ, BJ/5TA), an
embryo intestine cell line (I407) and an embryo kidney cell line
(HEK293), and 23 tumoral cell lines from 13 diﬀerent tissues
were analyzed: prostate carcinoma (LNCAP, DU145), osteo-
sarcoma (U2OS, SAOS2), lung carcinoma (A549), colon car-
cinoma (HCT116, HCT116/E6N7), colon adenocarcinoma
(COLO 205, HT29, LOVO), cervix carcinoma (HeLa), cervix
adenocarcinoma (C33A), ovary carcinoma (A2780), breast
adenocarcinoma (MCF7), gastric carcinoma (GTL16), pan-
creas adenocarcinoma (BX-PC3), pancreas carcinoma (PANC-
1), bladder carcinoma (HT1197), kidney carcinoma (CAKI 2),
skin carcinoma (A431, A431/ST2) andT cell lymphoma (U937).
All cell lines analyzed expressed signiﬁcant levels of either
p84N5 or p84N5s (Fig. 2). It is noteworthy that p84N5 andp84N5s are diﬀerentially expressed in distinct cell lines, sug-
gesting a speciﬁc regulation of each isoform within a cellular
context.3.4. P84N5, but not the short isoform p84N5s, is cell cycle
regulated
P84N5 has been reported to bind Rb protein that plays a
crucial role in cell cycle entry and progression [5]. We therefore
investigated expression levels of p84N5 and p84N5s during cell
cycle in NHDF. NHDF cells were starved by serum depriva-
tion and released in serum-containing medium in order to
obtain synchronous populations of diﬀerent cell cycle phases.
The cells were collected before starvation (As), during quies-
cence (Qui) and 24, 32 and 56 h after release. Samples were
processed for ﬂow cytometry analysis of DNA content to
conﬁrm synchronization and further analyzed by Western blot
and RT-PCR.
More than 90% of serum starved cells were in G1 phase. 24 h
after release, the cell population was enriched in S-phase cells.
32 h after release, the population was enriched in G2/M-phase
cells and 56 h after release the cell population was undistin-
guishable from an asynchronous cell population (Fig. 3). The
expression of p84N5, cyclin D1 and cyclin B1 in the same
samples was quantiﬁed by Western blot (Fig. 3). As expected,
cyclin D1 is speciﬁcally expressed during G1–S transition,
whereas cyclin B1 is highly expressed in G2–M transition [16].
P84N5 protein signiﬁcantly decreased during starvation, but it
was restored to physiological levels 24 h after release, without
any further modulation at the following time points; its
expression followed a kinetic similar to cyclin D1.
The same samples were analyzed by RT-PCR to detect
mRNA expression levels of either p84N5 or the short isoform
p84N5s. As shown in Fig. 3, the analysis conﬁrmed that cyclin
D1 and cyclin B1 mRNAs are cell cycle regulated. Similarly,
p84N5 mRNA levels signiﬁcantly decreased during starvation,
but they were restored to physiological levels 24 h after release,
corresponding to the re-entry into S-phase. On the contrary,
p84N5s mRNA levels did not signiﬁcantly change at any time
points. These observations suggest that full-length p84N5
mRNA, but not p84N5s mRNA, is regulated during cell cycle
progression.3.5. P84N5-GFP and GFP-p84N5 chimeras shuttle between the
nucleus and the cytoplasm
Since its identiﬁcation, p84N5 has been characterized as a
nuclear protein [8]. By immunoﬂuorescence analysis of p84N5-
Myc transfected cells, we detected nuclear localization of
p85N5 in the majority of cells. However, in a small but reliable
fraction of transfected cells, both overexpressed and endoge-
nous p84N5 localized to the cytoplasm (data not shown).
To further investigate this phenomenon, we created p84N5-
GFP and GFP-p84N5 chimera proteins (Fig. 4). As expected,
both p84N5-GFP and GFP-p84N5 transfected cells showed
nuclear localization (data not shown); this conﬁrmed that the
addition of GFP portion to p84N5 protein did not aﬀect lo-
calization. Nevertheless, in a reliable fraction of transfected
cells both p84N5-GFP and GFP-p84N5 presented cytoplas-
matic localization (data not shown). Both p84N5-GFP and
GFP-p84N5 induced signiﬁcant programmed cell death in
comparison to GFP-transfected cells, at levels comparable to
p84N5 alone (data not shown). These results indicate that
Fig. 2. p84N5 (upper panel) and p84N5s (lower panel) mRNA relative expression was quantiﬁed by RT-PCR in 28 cell lines. Data represent the
target gene expression values expressed as unitless fold changes as compared to a calibrator sample, represented by a cDNA mix of 12 human tissues,
both normalized by the relative housekeeping gene expressions. Data reported represent the average of two replicates with respective error bars.
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aﬀected by fusion with GFP.
We then analyzed both p84N5-GFP and GFP-p84N5 lo-
calization in live cells by time lapse microscopy. Three cell
lines, namely HEK293, U2OS and HeLa, were transfected
with p84N5-GFP or GFP-p84N5 and followed by phase
contrast and ﬂuorescence microscopy. Surprisingly, we ob-
served that in all cell lines investigated, to diﬀerent extent, the
localization of both p84N5-GFP and GFP-p84N5 alterna-
tively changed between the nucleus and the cytoplasm, indi-
cating that p84N5 is able to cross the nuclear envelope as a
shuttle (data not shown, Supplementary information). As wefound the same shuttling mechanism in cells transfected with
both p84N5-GFP and GFP-p84N5, we will refer only to
p84N5-GFP in the next paragraphs.
Fig. 4 reports frames, exported from complete movies of 24
h showing representative live U2OS and 293 cells transfected
with p84N5-GFP. P84N5-GFP chimera was exported several
times from the nucleus to the cytoplasm and subsequently re-
imported, being nuclear localization by far the most frequent.
To note, the nuclear export inhibitor leptomycin B [17] did not
aﬀect p84N5 localization (data not shown). Further experi-
ments are needed to clarify the detailed mechanistic insights of
the observed p84N5 shuttling and eventually to discover pro-
Fig. 3. (A) NHDF cells were serum starved and released; cells were collected at the indicated times after release and processed for ﬂow cytometry
analysis of DNA content. The percentages of cells in G1, S and G2/M phases are reported. p84N5, a-Tubulin, cyclin D1 and cyclin B1 were detected
by western blot. As indicates asynchronous. Data represent the target gene expression values expressed as unitless fold changes as compared to a
calibrator sample, normalized by the relative housekeeping gene expressions; all time points are reported as compared to asynchronous cells values
set at one. Data reported represent the average of two replicates with respective error bars. (B) Relative mRNA expression levels of p84N5, p84N5s,
cyclin D1 and cyclin B1, in the same samples of panel A, were quantiﬁed by RT-PCR. Qui indicates quiescent.
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exportins.
The localization of p84N5 during apoptosis was investi-
gated in single cells to address the question whether it un-
dergoes cytoplasmic translocation during apoptosis. P84N5
transfected U2OS and SAOS2 cells were analyzed for two
diﬀerent parameters: apoptotic index and p84N5 localiza-
tion. As expected, the vast majority of transfected cells
showed nuclear staining of p84N5 (Fig. 4 and data not
shown). However, when analysis was restricted to apoptotic
cell population having caspase-3 activation (see Section 2),
most of them showed cytoplasmic localization of p84N5
protein (Fig. 4). This observation indicates that p84N5 ac-
tually translocates to the cytoplasm during the early phaseof apoptosis execution that is characterized by caspase-3
activation.4. Discussion
In this letter, we report three main novel evidences on p84N5
protein that better deﬁne its mechanism of action. First, the
existence of distinct alternatively spliced p84N5 isoforms. In-
terestingly, the p84N5 short isoform (p84N5s) encodes for a
protein lacking the DD and the pRb-binding domain. This
isoform localizes within the cytoplasm, was never found in the
nucleus, and does not retain the ability to induce apoptosis. It is
interesting to note that this same isoform was found in several
Fig. 4. (A) Schematic representation of the p84N5-GFP and GFP-p84N5 constructs. (B) CCD camera images of a representative live 293 (B) and
U2OS (C) cells transfected with p84-GFP, analyzed by time lapse microscopy; frames were taken every 15 min (obj. 32). (D) U2OS and SAOS cells
were transfected with p84-GFP and analyzed for two parameters: apoptotic index and p84N5 localization.
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three diﬀerent mammalian species. Moreover, p84N5 but not
p84N5s expression is downregulated in quiescent cells. This
may represent a mechanism of selective regulation of one iso-
form by alternative splicing that may lead to a diﬀerent ratio of
expression of the two isoforms during cell cycle.
Second, we show for the ﬁrst time that p84N5 expression,
but not p84N5s, is regulated during proliferation. To our
knowledge, this is the ﬁrst report of a DD containing molecule
that is upregulated at the level of both RNA and protein
during cell proliferation. We showed that the expression of
p84N5 is markedly reduced in non-proliferating cells.Third, in all cell lines analyzed (293, HeLa and U2OS) both
p84N5-GFP and GFP-p84N5 chimeras periodically oscillate
from the nucleus to the cytoplasm. The dynamic and syn-
chronization of p84N5 shuttling was surprising: this is the ﬁrst
report describing the real time study of a protein shuttling
from the nucleus to the cytoplasm and vice versa, repeated
over time. It is important to note that under the same exper-
imental conditions, we did not observe such a shuttling
mechanism for other GFP-fused chimera proteins that can
localize within the nucleus, either in stable or in transiently
transfected cell lines (data not shown). Moreover, we observed
a strong correlation between p84N5 cytoplasmic localization
F. Gasparri et al. / FEBS Letters 574 (2004) 13–19 19and apoptosis execution. However, further work is needed to
analyze the localization of endogenous p84N5 in live cells.
An explanation may be envisaged based on the observed
shuttling mechanism; p84N5 protein may possess a nuclear
export signal, or it associates with some factor that acts as
nuclear-cytoplasmatic shuttle. Preliminary experiments
showed that this mechanism is leptomycin B resistant (data not
shown), thus indicating that the traﬃcking is not CRM1-
dependent.
It is tempting to speculate that p84N5 may be somehow
involved in an ‘‘apoptotic checkpoint’’. In viable proliferating
cells, waves of p84N5 proteins shuttle from the nucleus to the
cytoplasm. In the presence of an additional co-stimulus,
p84N5 may regulate pro-apoptotic signals. This would ﬁnally
result in cytoplasmatic caspases activation and apoptosis.
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